Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Pass Above 200 Day Moving Average – What’s Next?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.27 and traded as high as $8.50. Cumberland Pharmaceuticals shares last traded at $6.69, with a volume of 190,588 shares.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Wednesday, June 24th. Wall Street Zen lowered shares of Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Cumberland Pharmaceuticals Price Performance

The company has a market cap of $95.53 million, a P/E ratio of -9.04 and a beta of 0.13. The company’s 50-day moving average is $7.19 and its two-hundred day moving average is $5.29.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.07). The business had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $8.50 million. Cumberland Pharmaceuticals had a negative net margin of 34.40% and a negative return on equity of 28.81%.

Cumberland Pharmaceuticals Announces Dividend

The business also recently announced a dividend, which was paid on Friday, July 31st. Investors of record on Thursday, July 23rd were issued a $1.50 dividend.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of CPIX. BlackRock Inc. purchased a new stake in Cumberland Pharmaceuticals during the second quarter valued at $412,000. Bank of New York Mellon Corp bought a new position in shares of Cumberland Pharmaceuticals during the second quarter worth $379,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of Cumberland Pharmaceuticals during the first quarter valued at about $66,000. Dimensional Fund Advisors LP increased its stake in Cumberland Pharmaceuticals by 1.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 276,359 shares of the specialty pharmaceutical company’s stock worth $898,000 after acquiring an additional 4,081 shares during the last quarter. Finally, Perceptive Advisors LLC purchased a new stake in Cumberland Pharmaceuticals during the fourth quarter valued at $1,358,000. 15.51% of the stock is currently owned by hedge funds and other institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.